TY - JOUR
T1 - Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis
T2 - Preliminary data
AU - Casadio, Valentina
AU - Calistri, Daniele
AU - Tebaldi, Michela
AU - Bravaccini, Sara
AU - Gunelli, Roberta
AU - Martorana, Giuseppe
AU - Bertaccini, Alessandro
AU - Serra, Luigi
AU - Scarpi, Emanuela
AU - Amadori, Dino
AU - Silvestrini, Rosella
AU - Zoli, Wainer
PY - 2013/11
Y1 - 2013/11
N2 - Objectives: Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. Materials and methods: UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc, BCAS1, and HER2, were quantified by real time PCR. Results: At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61-0.85), and a specificity of 0.84 (95% CI 0.71-0.97) in healthy individuals and 0.83 (95% CI 0.72-0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739-0.930) for healthy individuals and 0.796 (95% CI 0.707-0.885) for symptomatic patients. Conclusions: These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an "at risk" population of symptomatic individuals.
AB - Objectives: Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early bladder cancer diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early bladder cancer diagnosis. Materials and methods: UCF DNA was isolated from 51 bladder cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc, BCAS1, and HER2, were quantified by real time PCR. Results: At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61-0.85), and a specificity of 0.84 (95% CI 0.71-0.97) in healthy individuals and 0.83 (95% CI 0.72-0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739-0.930) for healthy individuals and 0.796 (95% CI 0.707-0.885) for symptomatic patients. Conclusions: These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive diagnosis of bladder cancer. Its diagnostic performance does not seem to vary significantly, even in an "at risk" population of symptomatic individuals.
KW - Bladder cancer
KW - Early diagnosis
KW - Urine cell-free DNA integrity
UR - http://www.scopus.com/inward/record.url?scp=84886249189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886249189&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2012.07.013
DO - 10.1016/j.urolonc.2012.07.013
M3 - Article
C2 - 23141783
AN - SCOPUS:84886249189
VL - 31
SP - 1744
EP - 1750
JO - Urologic Oncology
JF - Urologic Oncology
SN - 1078-1439
IS - 8
ER -